INTRODUCTION
The phagocyte NADPH oxidase is a multiprotein enzyme complex, which plays an essential role in innate immunity (reviewed in ref. [1] ). The NADPH oxidase is composed of a plasma membrane-associated flavocytochrome b, comprised of gp91 phox and p22 phox , and four cytosolic proteins (p40 phox , p47
phox , p67 phox , and Rac2) and catalyzes the transfer of electrons from NADPH to O 2 , resulting in the formation of superoxide anion (O 2
•-) and other reactive oxygen species (ROS) important for defense against microbial pathogens (reviewed in refs. [2] [3] [4] ). Chronic granulomatous disease (CGD), resulting from genetic defects in NADPH oxidase genes and characterized by recurrent infections in individuals with CGD, demonstrates the importance of the oxidase in innate host immunity [5, 6] . Although the NADPH oxidase is essential to host immunity, it has also been demonstrated that excessive phagocyte ROS are involved in the tissue injury associated with a number of chronic inflammatory diseases, including rheumatoid arthritis [7] and atherosclerosis [8, 9] . Therefore, a better understanding of the processes that regulate the formation of an active NADPH oxidase complex is essential to the development of effective treatments to control the damage associated with chronic inflammation. Monocyte/macrophages are known to play a key role in the inflammatory processes associated with rheumatoid arthritis and atherosclerosis (reviewed in refs. [8, 10, 11] ). Infiltration of stimulated T lymphocytes into target tissue is promptly followed by the appearance of monocytes, which subsequently differentiate into macrophages. Interaction between stimulated T lymphocytes and macrophages leads to macrophage activation and the production of large amounts of the proinflammatory cytokines IL-1 and TNF-␣ as well as ROS production via NADPH oxidase activation. ROS contribute to atherogenesis via direct lipid and lipoprotein oxidation, leading to foam cell formation [8] , and it has been demonstrated clearly that the monocyte/macrophage NADPH oxidase is a major source of ROS in atherosclerotic lesions [12] [13] [14] . Therefore, understand-ing mechanisms that regulate the NADPH oxidase in monocyte/macrophages is critical for identifying therapeutic approaches to address chronic inflammatory syndromes.
Although it has been observed that the expression of various NADPH oxidase proteins is up-regulated in monocytes and/or macrophages after TNF-␣ treatment [15] [16] [17] , little is known about the mechanisms involved in this process. Dusi et al. [16] reported that TNF-␣-induced expression of gp91 phox required the binding of PU.1 to the CYBB promoter but also demonstrated that the effect of TNF-␣ on O 2
•-production was unrelated to its effects on flavocytochrome b expression. Thus, up-regulation of NADPH oxidase activity by TNF-␣ is likely mediated through effects on the other oxidase proteins. Indeed, Green et al. [15] showed that expression of p47 phox and p67 phox protein was enhanced by TNF-␣ in murine bone marrowderived macrophages, and we demonstrated recently that treatment of human MonoMac1 cells with TNF-␣ resulted in the up-regulation of neutrophil cytosolic factor 2 (NCF2), the gene encoding p67 phox , required a novel TNF-␣-responsive region in the NCF2 promoter [18] . Thus, we proposed that transcriptional regulation of the genes encoding one or more of the NADPH oxidase cytosolic components played a key role in TNF-␣-induced up-regulation of monocyte/macrophage oxidase activity. As the transcription factor NF-B can be activated by TNF-␣ [19] and ROS [20] , these observations also raised the possibility of a positive-feedback mechanism, whereby TNF-␣ produced by activated macrophages could serve as an autocrine/paracrine regulator of oxidase gene expression, possibly through NF-B, resulting in increased production of O 2
•-and further activation of NF-B.
In the present report, we evaluated the role of NF-B as a regulator of NADPH oxidase activity in TNF-␣-treated human MonoMac1 monocytes and human primary monocytes. Our data show that TNF-␣ treatment induced expression of the NADPH oxidase genes NCF1, NCF2, and CYBB, resulting in increased expression of p47 phox , p67 phox , and gp91 phox (NOX2) and up-regulation of O 2
•-production. We also show this effect was primarily a result of activation of the NF-B pathway but did not involve the JNK or p38 MAPK pathways. The role of NF-B in the transcriptional regulation of three essential NADPH oxidase components in response to TNF-␣ is a novel finding and, given that NF-B can be activated by TNF-␣ as well as ROS, supports the concept of a positive-feedback mechanism, whereby TNF-␣-activated NF-B up-regulates NADPH oxidase activity, leading to an increase in ROS levels and further activation of NF-B.
MATERIALS AND METHODS

Materials
Recombinant human TNF-␣ was from Fitzgerald Industries International, Inc.
(Concord, MA, USA). IKK Inhibitor II (Wedelolactone), IKK Inhibitor III (BMS-345541), JNK Inhibitor I, JNK Inhibitor II, p38 MAPK inhibitor, and p38 MAPK Inhibitor III were from Calbiochem/EMD Biosciences (San Diego, CA, USA). Diogenes cellular luminescence enhancement system was from National Diagnostics (Atlanta, GA, USA). Taqman probes and primer sets were purchased from Applied Biosystems (Foster City, CA, USA). mAb 7D5 was a kind gift of Dr. Michio Nakamura (Nagasaki University, Nagasaki, Japan).
Cell culture
The human MonoMac1 cell line (DSM ACC252, German Microorganism and Cell Culture Collection, Braunschweig, Germany) was used for these studies due to their morphological, histochemical, phenotypic, and functional property similarities to mature monocytes (e.g., phagocytosis, FcR, and specific surface marker expression) [21] . MonoMac1 cells were grown in RPMI-1640 media supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 50 g/ml streptomycin, nonessential amino acids, and sodium pyruvate. Cells were seeded at 3-5 ϫ 10 5 cells/mL, 12-24 h prior to treatment.
Monocyte purification
Human blood monocytes were purified in accordance with a protocol approved by the Institutional Review Board at Montana State University (Bozeman, MT, USA). Briefly, mononuclear cells were isolated from peripheral blood of healthy donors using dextran sedimentation for 45 min., followed by Histopaque 1077 gradient separation, as described by Schulert and Allen [22] . The monocyte/lymphocyte layer was collected, washed twice with cold RPMI, and plated on FBS-coated, 60 mm Petri dishes at 10 7 cells/plate in RPMI-1640 media supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 50 g/ml streptomycin, nonessential amino acids, and sodium pyruvate. Petri dishes were coated with FBS overnight and washed twice with PBS immediately before use. After incubation of the cells for 4 h at 37°C and 5% CO 2 , the media containing nonadherent cells were removed and replaced with fresh media Ϯ TNF-␣ and/or inhibitor, as indicated. At the indicated times, monocytes were harvested by removing the media, washing with PBS, and incubating for 15-20 min in cold PBS containing 5% FBS and 0.02% EDTA to lift the cells. Monocytes were collected, washed with HBSS containing 10 mM Hepes, pH 7.4, and resuspended in the desired buffer for further analyses. Monocyte preparations contained ϳ10% lymphocytes and no granulocytes, as determined by microscopic analysis.
Measurement of O 2
•-production MonoMac1 cells and monocytes were plated for 12 h prior to treatment with media (control) or 20 ng/mL TNF-␣. At the indicated times, cells were harvested and washed three times in HBSS. Cells were resuspended in HBSS containing CaCl 2 and MgCl 2 (HBSS ϩ ), and O 2 •-production was determined using Diogenes, a cellular chemiluminescence system specific for O 2
•-detection [23] . Assays were performed in Corning half-area chemiluminescence plates, and each well contained 50 L Diogenes reagent, 2 ϫ 10 5 cells, and HBSS ϩ added to a final volume of 100 L, with each sample run in triplicate. The cells were activated by addition of 50 ng/mL PMA in the presence or absence of 5 U/mL bovine erythrocyte superoxide dismutase (SOD; Sigma Chemical Co., St. Louis, MO, USA), and the reactions were monitored for 2 h at 37°C using a Fluoroskan Ascent FL microtiter plate reader (Thermo Electron Corp., Waltham, MA, USA).
For inhibitor experiments, cells were plated as above but treated for 30 -60 min with inhibitor prior to TNF-␣ treatment and activation. O 2
•-production was determined, and the data were analyzed as described above.
Quantitative (q)RT-PCR
MonoMac1 cells were seeded at 4 ϫ 10 5 cells/mL, 24 h prior to TNF-␣ treatment. At the indicated times, total RNA was isolated from untreated and 20 ng/mL TNF-␣-treated cells using a RNeasy mini kit and subjected to qRT-PCR analysis using gene-specific Taqman probes and primers ( Table 1) . ␤-actin was used as the endogenous control, and IL-8 and TNF-␣ were used as positive controls for inhibitor assays. Predesigned probe and primer sets for ␤-actin, IL-8, and TNF-␣ were obtained from Applied Biosystems (Foster City, CA, USA). Samples were analyzed on a 7500 real-time PCR system (Applied Biosystems), and data are presented as relative mRNA levels with Time 0 and no TNF-␣ treatment set to 1.
For inhibitor assays, cells were treated with or without inhibitor for 30 -60 min prior to TNF-␣ treatment and subsequent qRT-PCR analysis. Data were analyzed as above.
Immunoblot analysis
Cells were treated with inhibitor, as indicated, prior to treatment with media (control) or 20 ng/mL TNF-␣ for 12 h. Cells were pelleted by centrifugation and resuspended in 5 mL Dulbecco's PBS (DPBS; Invitrogen, Carlsbad, CA, USA) and treated with diisopropylfluorophosphate (0.5 L/mL) for 15 min on ice. Subsequently, cells were washed with DPBS and resuspended in 1 mL relaxation buffer (10 mM NaCl, 100 mM KCl, 10 mM Hepes, pH 7.4) containing protease inhibitor cocktail (Sigma Chemical Co.), 625 M PMSF, and 1% octyl-␤-D-glucopyranoside. Detergent extracts were stirred for 30 min on ice and centrifuged for 30 min at 100,000 g, and supernatants were collected. Samples (25, 50 , or 100 g) were separated by SDS-PAGE on gradient gels and transferred to a nitrocellulose membrane as described [24] . Prestained molecular weight standards (Amersham Biosciences, Piscataway, NJ, USA) were included on all gels for reference. Previously characterized anti-p67 phox mAb 81.1 [25] , anti-gp91 phox mAb 54.1 [26] , p22 phox mAb 44.1 [26] , anti-p40 phox mAb 1.9 [27] , and anti-p47 phox polyclonal antibody R360 [25] were used to probe Western blots, followed by HRP-conjugated goat anti-mouse or anti-rabbit secondary antibodies (BioRad, Richmond, CA, USA) and chemiluminescence development. Developed blots were analyzed using an IS-1000 Alpha Imager digital imaging system (Alpha Innotech, San Leandro, CA, USA).
Flow cytometric analysis
MonoMac1 cells were treated with media (control) or 20 ng/mL TNF-␣ for 12 h, diluted by addition of 4 mL DPBS containing 5% heat-inactivated FCS and 7.5 mM sodium azide (FACS buffer), and incubated for 5 min. The cells were separated into three groups. One group received no treatment (cells only); one group was treated with Alexa 488-conjugated goat anti-mouse IgG secondary antibody (2°antibody) for 1 h on ice; and one group was treated for 1 h on ice with mAb 7D5, which recognizes an extracellular epitope on gp91 phox [28] , followed by washing and addition of secondary antibody for 1 h. Following a wash with FACS buffer, all samples were resuspended in 2 mL FACS buffer and analyzed using a FACScan flow cytometer (BD Biosciences, San Jose, CA, USA). The data are presented as mean fluorescence intensity. , respectively. JNK Inhibitor I (cell-permeable peptide) and JNK Inhibitor II (SP600125) inhibit the JNK pathway. JNK Inhibitor I has no effect on ERK1/2 or p38 activities with an IC 50 of ϳ1 M [31] , and JNK Inhibitor II exhibits over 300-fold greater selectivity for JNK, as compared with ERK1 and p38 MAPKs, and has a reported IC 50 of 40 -90 nM [32] . The inhibitors used for the p38 MAPK pathway were p38 MAPK Inhibitor III (ML3403) with a reported IC 50 of 0.38 M [33] and p38 MAPK inhibitor with a reported IC 50 of 35 nM [34] .
Analysis of inhibitor efficacy
MonoMac1 cells were seeded at 2 ϫ 10 5 cells/well in 96-well microtiter plates for 24 h, treated with buffer (control) or the indicated inhibitor for 30 -60 min, and then treated with media (control) or 20 ng/mL TNF-␣ treatment for 30 min. Cells were fixed and analyzed for total and phosphorylated forms of NF-B p65 (Ser 536), JNK, and p38 MAPK using specific colorimetric assay FACE kits (Active Motif, Carlsbad, CA, USA), according to the manufacturer's protocol. Absorbance was measured on a SpectraMax PLUS microtiter plate spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).
Statistical analysis
One-way ANOVA was performed on the indicated sets of data, followed by Tukey's post test for pair-wise comparisons (GraphPad Prism Software, San Diego, CA, USA). Differences at P Ͻ 0.05 were considered to be statistically significant and are indicated.
RESULTS
TNF-␣ treatment enhances PMA-stimulated O 2
•-
production by MonoMac1 cells
In previous studies investigating the transcriptional regulation of NCF2, we found that TNF-␣ treatment of various myeloid cell lines and primary monocytes resulted in an increase in NCF2 mRNA and p67 phox protein. We hypothesized that an increase in p67 phox expression may lead to an increased and/or prolonged production of O 2
•-. To further characterize the effects of TNF-␣ on NADPH oxidase activity in monocyte/ macrophages, we evaluated PMA-activated O 2
•-production in •-production was evident after ϳ6 h of TNF-␣ treatment and statistically significant by 10 h (Fig. 1B ). These data demonstrate that TNF-␣ pretreatment results in enhanced PMA-stimulated NADPH oxidase activity in MonoMac1 cells.
TNF-␣ treatment up-regulates NCF1, NCF2, and CYBB message in MonoMac1 cells
To determine if transcription of other NADPH oxidase genes, in addition to NCF2, was altered by TNF-␣ treatment, we analyzed the change in message for CYBA, CYBB, NCF1, NCF2, and NCF4 using qRT-PCR with TaqMan probes and primer sets specific for the individual oxidase genes (see Table  1 for sequences). As with NCF2, mRNA levels for NCF1 and CYBB also increased with TNF-␣ treatment (Fig. 2) . The increase in mRNA levels for NCF1 was statically significant after 3 h of TNF-␣ treatment and after 6 h for NCF2 and CYBB, relative to the corresponding samples with no TNF-␣ treatment. The largest fold change was seen for NCF1 message, with a ten-to 20-fold increase. The increase in NCF2 mRNA 
was three-to fivefold, and there was a smaller, yet consistent, approximate twofold change observed for CYBB mRNA. In contrast, no increase in message was apparent for CYBA or NCF4 (Fig. 2) , even after 24 h of TNF-␣ treatment (data not shown).
To determine if the changes in message levels for NCF1, NCF2, and CYBB corresponded to changes in protein expression, Western blot analysis was performed to compare oxidase protein expression in untreated and TNF-␣-treated MonoMac1 cells (Fig. 3) . Consistent with the increased mRNA levels observed for NCF1, NCF2, and CYBB, expression of these oxidase components also increased after TNF-␣ treatment (Fig.  3A) , and the relative changes in protein expression were confirmed by densitometric analysis of the blots (Fig. 3B) . The lack of change in mRNA levels for NCF4 and CYBA was consistent with the absence of change in their protein levels seen after TNF-␣ treatment (Fig. 3A) . As a result of the relatively small change in CYBB mRNA and protein levels, we also analyzed the amount of cell surface flavocytochrome b protein expression on cells treated with and without TNF-␣ using flow cytometry. Consistent with the degree of change observed for CYBB mRNA and gp91 phox protein, an increase in the amount of gp91 phox protein expressed on the cell surface with TNF-␣ treatment was observed (1.5-to twofold increase; Fig. 3C ). As monocyte/macrophages do not contain an intracellular pool of flavocytochrome b [35] , flow cytometry provides an accurate measure of the total flavocytochrome b in these cells. Overall, the correlation between the delayed timing of the increase in O 2
•-production and the increase in NCF1, NCF2, and CYBB MonoMac1 cells were treated without or with increasing concentrations of inhibitor prior to TNF-␣ treatment, and the phosphorylated forms of NF-B p65, JNK, and p38 MAPK as well as total NF-B p65, JNK, and p38 MAPK were measured. As seen in Figure 4 , there was a statistically significant increase in the levels of phosphorylated NF-B p65 in TNF-␣-treated cells versus untreated cells, whereas the levels of total NF-B p65 remained fairly constant in treated and untreated cells. NF-B p65 phosphorylation was inhibited effectively in TNF-␣-treated MonoMac1 cells by IKK Inhibitor II and IKK Inhibitor III at concentrations of 20 -50 M and 10 -20 M, respectively (Fig. 4) . The levels of phosphorylated JNK and p38 MAPK, but not total levels of these kinases, also increased after TNF-␣ treatment; however, these increases were not statistically significant, suggesting that TNF-␣ does not activate the JNK and p38 MAPK pathways as effectively as the NF-B pathway in MonoMac1 cells. Nevertheless, JNK phosphorylation was inhibited by JNK Inhibitors I and II in TNF-␣-treated MonoMac1 cells at concentrations of 1-2 M and 100 -150 nM, respectively (Fig. 4) , and p38 MAPK phosphorylation was inhibited effectively by p38 MAPK Inhibitor III and p38 MAPK inhibitor at concentrations of 0.6 -1 M and 100 -150 nM, respectively (Fig. 4) . Note that these con- centrations were within the range of published IC 50 concentrations for all of these inhibitors. Using the effective inhibitor concentrations determined above, we evaluated which pathway(s) were involved in TNF-␣-induced up-regulation of NCF2, NCF1, and CYBB transcription. Cells were treated with inhibitor prior to 6 h of TNF-␣ treatment, and total RNA was analyzed by qRT-PCR. As seen in Figure 5 , IKK Inhibitor II and IKK Inhibitor III effectively blocked TNF-␣-induced up-regulation of NCF2 mRNA at or below concentrations determined to be effective at blocking the NF-B pathway in these cells. In contrast, inhibitors of the JNK and p38 MAPK pathways did not inhibit TNF-␣-induced up-regulation of NCF2 mRNA, even at concentrations higher than those determined to be effective at blocking these respective pathways (data not shown).
We next evaluated the effects of IKK Inhibitors II and III on the changes in NCF1 and CYBB mRNA induced by TNF-␣ treatment using inhibitor concentrations determined to be effective at blocking TNF-␣-induced up-regulation of NCF2 mRNA. Similar to NCF2, both IKK inhibitors completely blocked TNF-␣-induced up-regulation of NCF1 and CYBB message (Fig. 5) . In contrast, neither of the JNK or p38 MAPK pathway inhibitors affected the TNF-␣-induced up-regulation of NCF1 or CYBB mRNA at or above concentrations determined to be effective in blocking these respective pathways (data not shown).
Immunoblotting was performed to determine if the decrease in oxidase mRNAs after IKK inhibitor treatment led to a corresponding decrease in oxidase protein expression. Cells were treated with inhibitor prior to TNF-␣ treatment, and total cell lysates were analyzed. As shown in Figure 6 , treatment with both IKK inhibitors inhibited TNF-␣-induced up-regulation of p67 phox , p47 phox , and gp91 phox expression. Although inhibitor-treated samples showed basal p47 phox protein expression was similar to that of control cells (no inhibitor, no TNF-␣), basal p67 phox and gp91 phox protein expression in inhibitor-treated samples was below that of untreated cells, suggesting that NCF2 and CYBB basal expression may also be regulated, in part, via the NF-B pathway. This result is consistent with recent studies demonstrating that NF-B was required for basal as well as LPS/IFN-␥-stimulated CYBB expression in murine J774.A1 cells [38] . Overall, the ability of NF-B pathway inhibitors to block TNF-␣-induced up-regulation of NCF2, NCF1, and CYBB mRNA and corresponding protein in MonoMac1 cells clearly demonstrates that this response is mediated through the NF-B pathway.
To verify the results observed with the small-molecule inhibitors of the NF-B pathway, we attempted to block the NF-B pathway by transiently transfecting MonoMac1 cells with a dominant-negative IB␣ expression plasmid. However, the low transfection efficiency in MonoMac1 cells did not allow for equal or greater levels of expression of dominant-negative IB␣ protein relative to endogenous IB␣, as determined by Western blot analysis (data not shown). Therefore, to determine if the IKK inhibitors were specific for the NF-B pathway, we analyzed changes in expression of the gene encoding TNF-␣, which is known to be regulated via the NF-B pathway in response to TNF-␣ (reviewed in ref. [36] ). MonoMac1 cells were treated with the IKK inhibitor prior to TNF-␣ treatment for 6 h, and relative levels of TNF-␣ mRNA were determined using qRT-PCR. As seen in Figure 7 (upper panels), the levels of TNF-␣ mRNA increased approximately sevenfold in response to TNF-␣ treatment, and this increase was inhibited completely by IKK Inhibitor III. Similar inhibition was seen after treatment with IKK Inhibitor II (data not shown). In contrast, treatment with p38 Inhibitor III did not affect the TNF-␣-dependent increase in TNF-␣ mRNA (Fig. 7 , upper right panel). IL-8 is also known to be up-regulated by TNF-␣, and studies have shown that this response can occur via p38 MAPK, NF-B, or both [39 -41] . Therefore, the effects of IKK and p38 inhibitors on TNF-␣-induced increases in IL-8 mRNA were also analyzed (Fig. 7, lower panels) . Although p38 Inhibitor III inhibited the TNF-␣-induced increase significantly in IL-8 mRNA, it did not ablate the response. In comparison, the TNF-␣-dependent increase in IL-8 mRNA was inhibited only slightly by IKK Inhibitor III (Fig. 7 , lower left panel) and IKK II Inhibitor (data not shown). Thus, these results are consistent with reports that IL-8 can be regulated via the p38 MAPK and NF-B pathways in response to TNF-␣. Altogether, these data confirm specificity of the pharmacological inhibitors to their respective pathways.
As a final verification of inhibitor specificity, we evaluated an inhibitor from each group in HeLa cells containing a NF-B-luciferase reporter [42] . IKK Inhibitor II completely blocked TNF-␣-induced up-regulation of the NF-B-luciferase reporter, whereas the JNK and p38 MAPK inhibitors had no effect on the luciferase reporter activity (Supplemental Fig.  S1 ). Thus, these data provide additional confirmation of the specificity of these inhibitors. Taken together, our results provide convincing evidence that the TNF-␣-induced transcriptional up-regulation of NCF1, NCF2, and CYBB and subsequent protein expression in MonoMac1 cells are mediated through the NF-B pathway. 
Inhibition of NF-B activation blocks TNF-␣-induced up-regulation of NADPH oxidase proteins and activity in human monocytes
In previous studies, we and others [16, 18] in MonoMac1 cells, we considered whether the response to TNF-␣ was also mediated by the NF-B pathway in human primary monocytes. Isolated blood monocytes were treated with IKK Inhibitor III prior to TNF-␣ treatment, and at the indicated times, cells were stimulated with PMA, and O 2 •-production was monitored. As seen in Figure 9A , TNF-␣-treated monocytes maintained their ability to generate O 2 •-over time in culture (f), and there was a time-dependent loss of oxidase activity in the control, non-TNF-␣-treated cells (e), and major differences were present at times Ͼ6 h. It is notable that treatment of monocytes with IKK Inhibitor III prior to TNF-␣ treatment (•) also resulted in a time-dependent loss in oxidase activity, which was similar in magnitude and kinetics to that observed in control, non-TNF-␣-treated cells (e), demonstrating that maintenance of NADPH oxidase activity in cultured monocytes required the NF-B pathway.
To confirm the loss in monocyte oxidase activity was a result of diminished oxidase protein expression, as demonstrated above in MonoMac1 cells, we evaluated oxidase protein expression in monocytes treated identically as in the oxidase assays described above. Consistent with oxidase activity, p67 phox , p47 phox , and gp91 phox expression was similar between samples out to ϳ6 h, regardless of treatment (Fig. 9B) . However, at 24 and 48 h, there were major differences in oxidase protein expression between control and TNF-␣-treated samples, which correlated directly with the relative levels of O 2
•-produced by these cells (Fig. 9A) . Likewise, inhibition of the NF-B pathway inhibited the ability of TNF-␣ to maintain oxidase protein expression in cultured primary monocytes, and protein expression in IKK Inhibitor III-treated cells was similar to or even below that of control cells at similar time-points. Furthermore, the reduced expression of oxidase protein was also consistent with the diminished levels of O 2
•-produced by these cells. It should be noted that the basal levels of p67 phox and gp91 phox expression were also reduced by IKK inhibitor treatment (Fig. 9B) . This result is similar to our observations in MonoMac1 cells (Fig. 6) , again suggesting that basal and TNF-␣-induced NCF2 and CYBB gene expression is regulated via the NF-B pathway. Overall, these results clearly demonstrate the physiological relevance of the NF-B pathway in TNF-␣-induced regulation of oxidase gene expression and O 2
•-production in human monocytes.
DISCUSSION
Although monocytes and neutrophils express the same phagocyte NADPH oxidase components, there are some notable differences in the regulation of the NADPH oxidase activity between these cell types [35, 43, 44] . While monocytes show a gradual increase in O 2 •-production, which peaks ϳ1 h after stimulation with soluble agonists [13] , the response in neutrophils peaks in 2-10 min [45] . In addition, after sufficient recovery, monocytes are capable of mounting an additional response, which is typically not the case for neutrophils [46] . Lastly, differences in regulation through alternative signal transduction pathways are likely, given the fact that activating agents of the monocyte/macrophage NADPH oxidase do not necessarily activate the neutrophil NADPH oxidase (reviewed in refs. [8, 43] ). These differences support the hypothesis that regulation of the NADPH oxidase contributes to the distinct roles of monocyte/macrophages and neutrophils in chronic versus acute inflammation, respectively [45, 47, 48] .
It is well established that the macrophage respiratory burst can be enhanced markedly by pre-exposure to priming agents, such as LPS, TNF-␣, or IFN-␥ [49 -51] . Although the mechanisms of priming are not understood completely, it has become increasingly clear that NADPH oxidase subunits can be transcriptionally up-regulated in response to certain cytokines (TNF-␣, IFN-␥, IL-15), leading to an increase in or prolonged production of O 2
•-by mature monocytes [15] [16] [17] [18] 38] . In previous studies, we demonstrated that NCF2 was transcriptionally regulated in TNF-␣-treated MonoMac1 cells. Here, we extend this observation by further evaluating the effects of TNF-␣ on NADPH oxidase activity and investigating the signaling mechanisms underlying this response in these cells and in primary monocytes. After ϳ10 h of TNF-␣ treatment, there was a significant increase in the levels of O 2 •-produced upon PMA activation relative to untreated, PMA-activated cells. The length of time required to observe a significant increase in TNF-␣-induced O 2
•-levels suggested that regulation of oxidase activity was, in part, at the transcriptional level. Indeed, analysis of changes in message and protein for NADPH oxidase subunits indicated significant changes in NCF1, NCF2, and CYBB mRNA were evident by 3-6 h and were followed by corresponding increases in p47 phox , p67 phox , and gp91 phox protein. Furthermore, the kinetics of up-regulation of these three NADPH oxidase subunits correlated directly with the enhancement of O 2
•-production after TNF-␣ treatment. The significantly larger increase in p47 phox and p67 phox protein levels (ten-to 20-and three-to fivefold, respectively) versus the relatively smaller change observed for gp91 phox protein (1.5-to threefold) after TNF-␣ treatment suggests that changes in expression of the two cytosolic components versus changes in flavocytochrome b expression may have a greater impact on the increase in O 2
•-production in TNF-␣-treated cells. This observation is consistent with other reports demonstrating that the amount of gp91 phox did not correlate with the functional capacity of the enzyme [52] and that oligonucleotide inhibition of gp91 phox expression induced by INF-␥ and TNF-␣ failed to contribute to changes in NADPH oxidase activity [16] .
To further elucidate the signal transduction pathway(s) involved in the transcriptional regulation of NCF1, NCF2, and CYBB in TNF-␣-treated MonoMac1 cells, we used pharmacological inhibitors to specifically block the NF-B, JNK, and p38 MAPK pathways. We found that TNF-␣-mediated upregulation of NCF1, NCF2, and CYBB gene expression and subsequent protein expression could be blocked by NF-B pathway inhibitors but not by inhibitors of the JNK or p38 MAPK pathways. In addition, inhibitor treatment resulted in a decrease in basal levels of p67 phox and gp91 phox protein, suggesting that basal expression of these proteins may also be regulated via the NF-B pathway. These results are consistent with a recent report demonstrating a role for NF-B in the basal, as well as LPS/IFN-␥-induced regulation of CYBB expression in murine J774.A1 monocyte/macrophages [38] . In their report, two NF-B-binding sites were identified in the mouse CYBB promoter, and putative, corresponding elements were noted in the human CYBB promoter [38] . However, functionality of the putative NF-B elements in the human CYBB promoter has not been determined. We searched the NCF1 and NCF2 promoters for NF-B elements similar in sequence to those identified in the murine CYBB promoter using the TF-SEARCH program [53] and identified one putative NF-B element corresponding in sequence to the murine CYBB NF-B1 element in each of the NCF1 and NCF2 promoters (Fig.  10) , both containing two nucleotide differences when compared with the mouse CYBB B1 promoter element. In any case, further studies are required to determine if NF-B binds to the putative B elements in the human NCF1, NCF2, and with the highest concentrations of p38 MAPK inhibitor, suggesting the possibility that the TNF-␣-induced increase in NADPH oxidase activity may also be regulated, to a slight degree, by the p38 MAPK pathway, a pathway shown to be important in regulating the NADPH oxidase activity in neutrophils via priming [54 -58] . Although this study does not completely rule out the possibility that some of the TNF-␣-induced ROS production in MonoMac1 cells is generated by other mechanisms (i.e., other NOX proteins or a mitochondrial source), our data clearly show that the majority of TNF-␣-induced increase in NADPH oxidase activity in MonoMac1 cells is regulated via the NF-B pathway and correlates well with the timing of transcriptional up-regulation of NCF1, NCF2, and CYBB gene expression. Previously, we found that TNF-␣ treatment of human blood monocytes induced an increase in NCF2 message and subsequent p67 phox protein expression [18] , which is consistent with our present findings and the conclusion that the enhancing effects of TNF-␣ on O 2
•-production are a result of regulation of NADPH oxidase gene expression. These results are generally consistent with previous reports demonstrating an increase in p67 phox and p47 phox protein in murine bone marrow-derived macrophages treated with TNF-␣ [15] , an increase in gp91 phox in THP-1 cells treated with IFN-␥/TNF-␣ [17] , and an increase in p47 phox and gp91 phox in monocytes treated with TNF-␣ [16] . It should be noted, however, that some differences were observed when comparing our p67 phox expression data in monocytes with studies published previously. For example, Dusi et al. [16] reported similar up-regulation of p47 phox and gp91 expression in TNF-␣-treated monocytes at 48 h; whereas, they observed no differences in p67 phox protein levels compared with control cells at 48 h. In contrast, we found that p67 phox expression is maintained by TNF-␣, which would be required for maintenance of oxidase activity. The reason for this difference is not clear, but may simply be a result of differences in sample preparation. Another possibility may be variability between cell preparations, as we observed donor-to-donor variability in the timing and/or changes of oxidase protein expression and activity. However, regardless of this variability between donors, TNF-␣ treatment consistently resulted in the maintenance of p67 phox , p47 phox , and gp91
phox protein levels and oxidase activity, and this response was blocked completely by NF-B pathway inhibitors. Thus, the maintenance of p67 phox , p47 phox , and gp91 phox protein levels in TNF-␣-treated monocytes is mediated through the NF-B pathway, demonstrating the physiological relevance of this pathway in transcriptional regulation of oxidase gene expression and subsequent enhanced O 2
•-production.
Chronic inflammatory diseases, such as atherosclerosis and rheumatoid arthritis, are characterized by the migration of blood-derived inflammatory cells into the target tissue, where they generate ROS and other inflammatory products [7] . It is also well established that NF-B can be activated by NADPH oxidase through ROS intermediates [20, 59 -61] . This study provides evidence that transcriptional regulation of three essential NADPH oxidase components in response to TNF-␣ is mediated through the NF-B pathway. This novel finding, as well as our previous study [18] , provides further evidence to support a positive-feedback model, whereby NF-B activation, as a result of TNF-␣ produced by activated macrophages, could lead to up-regulation of NADPH oxidase expression and subsequent O 2
•-production, which in turn, could further activate NF-B in the same cells (autocrine) and neighboring phagocytes (paracrine). As a consequence, this positive-feedback loop could result in sustained production of O 2 •-and contribute to the pathogenesis of chronic inflammatory diseases. Given the intricate relationship between NF-B and ROS in chronic inflammation, establishing the pathways that regulate the NADPH oxidase activity may eventually help to identify critical events associated with the pathogenesis of chronic inflammation.
